1.65
price up icon5.10%   0.08
after-market Dopo l'orario di chiusura: 1.64 -0.01 -0.61%
loading
Precedente Chiudi:
$1.57
Aprire:
$1.58
Volume 24 ore:
1.27M
Relative Volume:
1.56
Capitalizzazione di mercato:
$101.29M
Reddito:
$5.03M
Utile/perdita netta:
$-185.41M
Rapporto P/E:
-0.534
EPS:
-3.09
Flusso di cassa netto:
$-139.79M
1 W Prestazione:
+7.14%
1M Prestazione:
+7.84%
6M Prestazione:
+14.58%
1 anno Prestazione:
-89.09%
Intervallo 1D:
Value
$1.52
$1.70
Intervallo di 1 settimana:
Value
$1.45
$1.70
Portata 52W:
Value
$1.1001
$16.10

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Nome
Pliant Therapeutics Inc
Name
Telefono
650-481-6770
Name
Indirizzo
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Dipendente
171
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
PLRX's Discussions on Twitter

Confronta PLRX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.65 92.70M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.61 105.69B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.07 61.52B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
569.17 60.69B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
837.28 50.05B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
318.02 35.25B 4.56B -176.77M 225.30M -1.7177

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-10-10 Downgrade JP Morgan Neutral → Underweight
2025-03-04 Ripresa Cantor Fitzgerald Neutral
2025-03-04 Downgrade Needham Buy → Hold
2025-03-03 Downgrade Leerink Partners Outperform → Market Perform
2025-03-03 Downgrade Stifel Buy → Hold
2025-02-10 Downgrade Canaccord Genuity Buy → Hold
2025-02-10 Downgrade Citigroup Buy → Neutral
2025-02-10 Downgrade H.C. Wainwright Buy → Neutral
2025-02-10 Downgrade JP Morgan Overweight → Neutral
2025-02-10 Downgrade Oppenheimer Outperform → Perform
2025-02-10 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-02-10 Downgrade Wells Fargo Overweight → Equal Weight
2024-09-09 Ripresa Leerink Partners Outperform
2023-12-08 Iniziato Wells Fargo Overweight
2023-05-18 Iniziato Canaccord Genuity Buy
2023-04-13 Iniziato Robert W. Baird Outperform
2022-12-14 Iniziato Stifel Buy
2022-12-07 Iniziato JP Morgan Overweight
2022-09-01 Iniziato Citigroup Buy
2022-07-20 Iniziato SVB Leerink Outperform
2022-05-25 Iniziato Cantor Fitzgerald Overweight
2021-12-10 Iniziato Oppenheimer Outperform
2021-11-24 Iniziato RBC Capital Mkts Outperform
2021-11-03 Iniziato H.C. Wainwright Buy
2021-04-20 Iniziato BTIG Research Buy
2021-04-05 Iniziato Citigroup Buy
2020-06-29 Iniziato Citigroup Buy
2020-06-29 Iniziato Cowen Outperform
2020-06-29 Iniziato Needham Buy
2020-06-29 Iniziato Piper Sandler Overweight
Mostra tutto

Pliant Therapeutics Inc Borsa (PLRX) Ultime notizie

pulisher
04:39 AM

Evaluating Pliant Therapeutics Inc. with trendline analysisProfit Target & Fast Exit/Entry Strategy Plans - newser.com

04:39 AM
pulisher
Oct 15, 2025

Does Pliant Therapeutics Inc. stock trade at a discount to peers - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Has Pliant Therapeutics Inc. found a price floor2025 Trading Recap & Growth Oriented Trade Recommendations - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

What to expect from Pliant Therapeutics Inc. in the next 30 daysWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How sustainable is Pliant Therapeutics Inc. stock dividend payoutJuly 2025 Earnings & Weekly Chart Analysis and Guides - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Pliant Therapeutics Inc. stock trend forecastJuly 2025 Big Picture & Weekly Market Pulse Updates - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Price momentum metrics for Pliant Therapeutics Inc. explainedJuly 2025 Volume & Weekly Market Pulse Alerts - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

How Pliant Therapeutics Inc. (9PT) stock reacts to new regulationsJuly 2025 News Drivers & Risk Managed Investment Strategies - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Technical signs of recovery in Pliant Therapeutics Inc.Market Volume Summary & Fast Exit/Entry Strategy Plans - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Can Pliant Therapeutics Inc. stock maintain operating marginsJuly 2025 Action & Verified Swing Trading Watchlist - newser.com

Oct 14, 2025
pulisher
Oct 12, 2025

Will Pliant Therapeutics Inc. bounce back from current supportJuly 2025 PostEarnings & Community Consensus Trade Alerts - newser.com

Oct 12, 2025
pulisher
Oct 12, 2025

Can you recover from losses in Pliant Therapeutics Inc.Volume Spike & Weekly Watchlist of Top Performers - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

What analysts say about Pliant Therapeutics Inc stockDividend Cut Warnings & Low Risk Investment Plans - earlytimes.in

Oct 11, 2025
pulisher
Oct 11, 2025

Pliant Therapeutics' (PLRX) Underweight Rating Reiterated at JPMorgan Chase & Co. - MarketBeat

Oct 11, 2025
pulisher
Oct 10, 2025

JPMorgan downgrades Pliant Therapeutics stock rating to Underweight from Neutral - Investing.com Canada

Oct 10, 2025
pulisher
Oct 10, 2025

Pliant Therapeutics Shares Fall After JPMorgan Downgrade - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

Pliant Therapeutics Inc. stock outlook for YEARMarket Growth Review & Capital Protection Trade Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Allogene, Pliant down as J.P. Morgan cuts to Underweight on uncertain outlook - Seeking Alpha

Oct 10, 2025
pulisher
Oct 10, 2025

JPMorgan Downgrades Pliant Therapeutics to Underweight From Neutral - MarketScreener

Oct 10, 2025
pulisher
Oct 10, 2025

PLRX Downgraded by JP Morgan: Today's Key Analyst Rating Update - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Order flow analysis tools used on Pliant Therapeutics Inc.July 2025 Intraday Action & Community Consensus Stock Picks - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Pliant Therapeutics (NASDAQ:PLRX) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 09, 2025

Is Pliant Therapeutics Inc. (9PT) stock testing key supportPortfolio Growth Summary & Accurate Buy Signal Notifications - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Pliant Therapeutics Inc. (9PT) stock a top pick for value investorsGlobal Markets & Free Reliable Trade Execution Plans - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Detecting price anomalies in Pliant Therapeutics Inc. with AIJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com

Oct 09, 2025
pulisher
Oct 06, 2025

Why Pliant Therapeutics Inc. (9PT) stock attracts wealthy investorsJuly 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com

Oct 06, 2025
pulisher
Oct 03, 2025

Published on: 2025-10-03 01:17:50 - newser.com

Oct 03, 2025

Pliant Therapeutics Inc Azioni (PLRX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Pliant Therapeutics Inc Azioni (PLRX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Cummings Keith Lamont
Chief Financial Officer
Jan 17 '25
Sale
11.20
20,148
225,680
262,608
Hull Hans
Chief Business Officer
Jan 17 '25
Sale
11.20
15,936
178,501
211,558
Lefebvre Eric
Chief Medical Officer
Jan 17 '25
Sale
11.20
18,478
206,974
194,574
Cheung Lily
Chief Human Resource Officer
Jan 17 '25
Sale
11.20
3,740
41,892
24,550
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 17 '25
Sale
11.20
13,270
148,639
80,774
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 22 '25
Sale
10.99
10,230
112,462
70,544
$21.97
price down icon 2.96%
$87.31
price down icon 0.95%
$32.75
price up icon 0.09%
$105.08
price up icon 0.71%
$163.19
price down icon 0.21%
biotechnology ONC
$318.02
price up icon 0.59%
Capitalizzazione:     |  Volume (24 ore):